The standard of care for many
patients with advanced breast
cancer (BC )is gradually
evolving from empirical
treatment based on clinicalpathological
characteristics to
the use of targeted approaches
based on the molecular profile
of the tumor.
In the last decade, an
increasing number of
molecularly targeted drugs
have been developed for the
treatment of metastatic BC.
These drugs target specific
molecular abnormalities that
confer to cancer cells a survival
advantage. Interestingly,
the ability to perform multigene
testing for a range of
molecular alterations may
provide an opportunity to
clarify the mechanisms of
treatment response, to find the
strategies to overcome
treatment resistance and thus,
to identify patients who are
more likely to develop relapse
and who may be candidates for
matched targeted therapies.
The main aim of this study is to
find prognostic and predictive
molecular biomarkers for the
management of metastatic BC
patients in clinical practice
